ESC Premium Access

The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Presentation

About the speaker

Mr Paul Hendriks

Erasmus University Medical Centre, Rotterdam (Netherlands (The))
0 follower

73 more presentations in this session

The novel noninvasive method for prediction of long-term specific therapy efficacy in patients with IPAH and inoperable CTEPH

Speaker: Mrs I. Lyapina (Kemerovo, RU)

Thumbnail

Early and long term prognostic accuracy of 4 acute pulmonary embolism mortality risk scores

Speaker: Doctor L. Oliveira (Ponta Delgada, PT)

Thumbnail

Novel genetic and molecular pathways in pulmonary arterial hypertension associated with connective tissue disease

Speaker: Doctor I. Hernandez Gonzalez (Valladolid, ES)

Thumbnail

Role of echocardiography to avoid misclassification of pulmonary hypertension associated with left heart disease as precapillary pulmonary hypertension.

Speaker: Assistant Professor J. Grignola Rial (Montevideo, UY)

Thumbnail

Survival of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension listed for lung transplantation

Speaker: Doctor I. Magnani (Bologna, IT)

Thumbnail

Access the full session

Pulmonary circulation, pulmonary embolism, right heart failure e-posters

Speakers: Mr P. Hendriks, Mrs I. Lyapina, Doctor L. Oliveira, Doctor I. Hernandez Gonzalez, Assistant Professor J. Grignola Rial...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

COVID-19 and the risk of thrombosis.

27 August 2021

ESC Premium Access

The COVID-19 pandemic: a multiple (cardiovascular) hit?

27 August 2021

ESC Premium Access

Impact of COVID-19 pandemics upon pulmonary hypertension patients: insights from BNP-PL national database

27 August 2021

This platform is supported by

logo Novo Nordisk